NASDAQ:NUVA

NuVasive - NUVA Stock Forecast, Price & News

$54.02

+0.53 (+0.99%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $52.22
▼
$54.62
50-Day Range: $46.84
▼
$54.04
52-Week Range: $45.45
▼
$64.43

Volume: 586,153 shs
Average Volume: 544,291 shs
Market Capitalization: $2.81 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.91

NuVasive MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 14.6% Upside
$61.91 Price Target
Short Interest: Bearish
6.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.65
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 13.00%
From $2.23 to $2.52 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

1083rd out of 1,125 stocks

Surgical & Medical Instruments Industry

106th out of 113 stocks

2.3

Analyst's Opinion

Consensus Rating
NuVasive has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $61.91, NuVasive has a forecasted upside of 14.6% from its current price of $54.02.
Amount of Analyst Coverage
NuVasive has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.80% of the float of NuVasive has been sold short.
Short Interest Ratio / Days to Cover
NuVasive has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in NuVasive has recently increased by 1.76%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
NuVasive does not currently pay a dividend.
Dividend Growth
NuVasive does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NUVA.

2.0

News and Social Media Coverage

News Sentiment
NuVasive has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for NuVasive this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for NUVA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added NuVasive to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NuVasive insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.47% of the stock of NuVasive is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NuVasive are expected to grow by 13.00% in the coming year, from $2.23 to $2.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NuVasive is -67.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NuVasive is -67.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
NuVasive has a PEG Ratio of 2.13. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
NuVasive has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

NuVasive Stock Up 1.0 %

NUVA Stock traded up $0.53 during trading hours on Monday, hitting $54.02. The company's stock had a trading volume of 586,153 shares, compared to its average volume of 544,291. The company has a quick ratio of 0.70, a current ratio of 1.17 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $2.81 billion, a PE ratio of -67.53, a price-to-earnings-growth ratio of 2.13 and a beta of 1.14. NuVasive has a 12 month low of $45.45 and a 12 month high of $64.43. The stock has a 50 day moving average price of $50.80 and a two-hundred day moving average price of $52.77.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of NuVasive from $50.00 to $55.00 in a report on Friday, August 5th. Morgan Stanley dropped their price objective on shares of NuVasive from $62.00 to $54.00 and set an "equal weight" rating on the stock in a research note on Friday, July 15th. Piper Sandler dropped their price objective on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. Finally, Truist Financial dropped their price objective on shares of NuVasive to $63.00 in a research note on Friday, July 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, NuVasive presently has a consensus rating of "Hold" and a consensus price target of $61.75.

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Stock News Headlines

August 15, 2022 | americanbankingnews.com

NuVasive, Inc. (NASDAQ:NUVA) Receives Consensus Rating of "Hold" from Brokerages

August 9, 2022 | finance.yahoo.com

NuVasive Announces Departure of Chief Commercial Officer

August 9, 2022 | americanbankingnews.com

NuVasive (NASDAQ:NUVA) Given New $55.00 Price Target at Canaccord Genuity Group

August 7, 2022 | finance.yahoo.com

NuVasive (NASDAQ:NUVA) shareholders have endured a 23% loss from investing in the stock five years ago

August 7, 2022 | americanbankingnews.com

Piper Sandler Cuts NuVasive (NASDAQ:NUVA) Price Target to $60.00

August 5, 2022 | nasdaq.com

NuVasive, Inc. Q2 Earnings Summary

August 4, 2022 | rttnews.com

VNDA On Watch, NUVA Q2 Results Miss Estimates, MRTX Awaits FDA Decision...

August 4, 2022 | investing.com

NuVasive Misses Q2 EPS by 9c, Offers Guidance By Investing.com - Investing.com

August 3, 2022 | finance.yahoo.com

NuVasive (NUVA) Lags Q2 Earnings Estimates

August 3, 2022 | uk.investing.com

NuVasive Misses Q2 EPS by 9c, Offers Guidance By Investing.com - Investing.com UK

August 3, 2022 | benzinga.com

Recap: NuVasive Q2 Earnings - Benzinga

August 3, 2022 | nasdaq.com

MedTech Stocks to Watch for Earnings on Aug 3 - Nasdaq

August 2, 2022 | seekingalpha.com

NuVasive Q2 2022 Earnings Preview (NASDAQ:NUVA) - Seeking Alpha

August 1, 2022 | americanbankingnews.com

NuVasive (NUVA) to Release Quarterly Earnings on Wednesday

July 28, 2022 | benzinga.com

NuVasive to Participate in Canaccord Genuity 42nd Annual Growth Conference - Benzinga

July 28, 2022 | finance.yahoo.com

NuVasive to Participate in Canaccord Genuity 42nd Annual Growth Conference

July 27, 2022 | nasdaq.com

Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline - Nasdaq

July 27, 2022 | finance.yahoo.com

Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline

July 26, 2022 | finance.yahoo.com

Clinical Study Validates NuVasive Porous Interbody Implant and Synthetic Bone Graft Substitute as Cost-effective Solution for Lateral Lumbar Interbody Fusions

July 25, 2022 | globenewswire.com

Artificial Cervical Intervertebral Disc Market Size Worth $4.37 Bn Globally, by 2028 at 18.0% CAGR - Exclusive Report by The Insight Partners - GlobeNewswire

July 25, 2022 | finance.yahoo.com

Global Orthopedic Implant Market Garnered USD 47 Billion in 2021 and is Expected to Grow with a CAGR of ~7% During 2022-2031; Market to Grow on Back of Rising Number of Geriatric People with Orthopedic Disorders - Yahoo Finance

July 25, 2022 | americanbankingnews.com

NuVasive (NASDAQ:NUVA) Price Target Cut to $63.00 by Analysts at Truist Financial

July 14, 2022 | streetinsider.com

SMAIO: First-half 2022 Sales up +28% to €1.3 Million - StreetInsider.com

July 12, 2022 | benzinga.com

Global Spinal Fusion Devices Market to Surpass US$ 13,182.25 Million by 2030 - Coherent Market Insights - Benzinga

July 12, 2022 | finance.yahoo.com

SMAIO: First-half 2022 Sales up +28% to €1.3 Million - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings: 11/09/2021
Today: 8/16/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:NUVA
CUSIP: 67070410
CIK: 1142596
Web: www.nuvasive.com
Phone: (858) 909-1800
Fax: 800-475-9134
Employees: 2,900
Year Founded: 1997

Price Target and Rating

Average Stock Price Forecast: $61.91
High Stock Price Forecast: $83.00
Low Stock Price Forecast: $54.00
Forecasted Upside/Downside: +14.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 24.22
P/E Growth: 2.13
Net Income: $-64,090,000.00
Net Margins: -3.41%
Pretax Margin: -2.96%
Return on Equity: 11.12%
Return on Assets: 4.20%

Debt

Debt-to-Equity Ratio: 0.54
Current Ratio: 1.17
Quick Ratio: 0.70

Sales & Book Value

Annual Sales: $1.14 billion
Price / Sales: 2.47
Cash Flow: $4.80 per share
Price / Cash Flow: 11.25
Book Value: $15.37 per share
Price / Book: 3.51

Miscellaneous

Outstanding Shares: 52,061,000
Free Float: 51,816,000
Market Cap: $2.81 billion
Optionable: Optionable
Beta: 1.14

Social Links

Key Executives

Mr. J. Christopher Barry (Age 48)
CEO & Director
Comp: $2.93M
Mr. Matthew K. Harbaugh (Age 52)
Exec. VP & CFO
Comp: $939.39k
Mr. Dale A. Wolf (Age 42)
Sr. VP of Global Operations
Comp: $679.16k
Mr. Nathaniel B. Sisitsky Esq. (Age 47)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $787.93k
Mr. Massimo Calafiore
Exec. VP & Chief Commercial Officer
Mr. Marc Rosenbaum (Age 50)
VP, Corp. Controller & Chief Accounting Officer
Mr. Ryan Donahoe
Sr. VP & Chief Technology Officer
Mr. Johnson Lai
Chief Information Officer
Ms. Juliet C. Cunningham
VP of Investor Relations
Mr. Michael Farrington
Sr. VP of Corp. Marketing, Brand & Communication

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings or view top-rated stocks.
What is NuVasive's stock price forecast for 2022?: 12 equities research analysts have issued 12 month target prices for NuVasive's stock. Their NUVA share price forecasts range from $54.00 to $83.00. On average, they expect the company's stock price to reach $61.91 in the next year. This suggests a possible upside of 14.6% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.
How have NUVA shares performed in 2022?: NuVasive's stock was trading at $52.48 at the beginning of 2022. Since then, NUVA stock has increased by 2.9% and is now trading at $54.01.
View the best growth stocks for 2022 here.
When is NuVasive's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our NUVA earnings forecast.
How were NuVasive's earnings last quarter?: NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings data on Tuesday, November, 9th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.54 by $0.22. The medical device company earned $270.84 million during the quarter, compared to the consensus estimate of $291.32 million. NuVasive had a positive trailing twelve-month return on equity of 11.12% and a negative net margin of 3.41%. During the same quarter last year, the firm posted $0.54 EPS.
How will NuVasive's stock buyback program work?: NuVasive announced that its Board of Directors has authorized a stock buyback program on Tuesday, November 9th 2021, which authorizes the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.5% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its shares are undervalued.
What guidance has NuVasive issued on next quarter's earnings?: NuVasive issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of $2.15-$2.45 for the period, compared to the consensus estimate of $2.31. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.
What is Chris Barry's approval rating as NuVasive's CEO?: 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).
What is NuVasive's stock symbol?: NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
Who are NuVasive's major shareholders?: NuVasive's stock is owned by many different retail and institutional investors. Top institutional investors include Paradice Investment Management LLC (2.28%), Loomis Sayles & Co. L P (1.57%), Stephens Investment Management Group LLC (1.54%), Northern Trust Corp (1.35%), Frontier Capital Management Co. LLC (1.32%) and Victory Capital Management Inc. (1.25%). Insiders that own company stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends.
How do I buy shares of NuVasive?: Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NuVasive's stock price today?: One share of NUVA stock can currently be purchased for approximately $54.01.
How much money does NuVasive make?: NuVasive (NASDAQ:NUVA) has a market capitalization of $2.81 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.
How many employees does NuVasive have?: The company employs 2,900 workers across the globe.
Does NuVasive have any subsidiaries?: The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
When was NuVasive founded?: NuVasive was founded in 1997.
How can I contact NuVasive?: NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

NuVasive - NUVA Stock Forecast, Price & News

NuVasive MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month